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Abstract
The American Cancer Society has estimated that in
2003, there will be approximately 239,600 new cases of
urologic cancer diagnosed and 54,600 urologic can-
cer–related deaths in the United States. To date, the
majority of research and therapy design have focused
on the microenvironment of the primary tumor site, as
well as the microenvironment of the metastatic or
secondary (target) tumor site. Little attention has been
placed on the interactions of the circulating tumor
cells and the microenvironment of the circulation (i.e.,
the third microenvironment). The purpose of this
review is to present the methods for the detection
and isolation of circulating tumor cells and to discuss
the importance of circulating tumor cells in the biology
and treatment of urologic cancers.
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Introduction to Circulating Tumor Cells and Metastasis
The progression of metastasis involves a complex series
of chemical, molecular, and physical events, resulting in
the ultimate deposition and proliferation of cancer cells at
distant targeted sites. The current paradigm of metastasis
describes the progression of cancer as the dissemination
of neoplastic tumor cells from the primary tumor to distant
target organs. The majority of cancer research over the
past century have focused on two predominant environ-
ments: 1) the tissue of origin where the neoplasm devel-
ops, known as the primary microenvironment; and 2) the
target tissue where cancer metastases occur, known as
the secondary microenvironment. The environment of the
circulatory system from the perspective of cancer metas-
tasis has been underappreciated until recently. The im-
portance of understanding how tumor cells derived from
solid tissues survive in transit through the mechanical
hardships of the circulation and avoid destruction by the
immune system is an essential step in cancer metastases
and, therefore, the circulatory system must be regarded as
the third microenvironment (Figure 1).
The impetus to explore the microenvironment of the circu-
latory system for invading tumor cells actually stems back
as far as the 19th century. In 1869, Ashworth [1] described
the presence of tumor-like cells in the peripheral blood of a
cancer patient at autopsy. Ashworth’s observations incited
interest in the process of metastasis and the mechanisms
of tumor cell dissemination. Paget [2], in 1889, was the first
to hypothesize a nonrandom pattern of neoplastic tumorigen-
esis and, as a result, developed the ‘‘seed and soil’’ theory
of cancer metastases, which stated that distinct subpopula-
tions of tumor cells were attracted to specific end-target organs
resulting in metastasis. Later, the ‘‘seed and soil’’ hypothesis
was redefined based on evidence suggesting that neoplas-
tic tumors contained a high degree of heterogeneity with
subpopulations of cells possessing different angiogenic, inva-
sive, and metastatic properties. Furthermore, the meta-
static process was shown to be selective for cells that
survived in the circulatory system and migrated to distant
end-target organs [3].
The predominant focus of cancer research has been to
target the neoplastic development and tumorigenesis within
the primary organ, as well as the affinity of tumor cells for the
metastatic site. However, accumulating evidence suggested
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that localized tumors begin shedding neoplastic tumor cells
into the circulation during early stages of the disease, with
distinct cell populations having the potential to develop
into metastatic disease [4–6]. Thus, there has been grow-
ing interest in identifying tumor cells in the circulation and
using the detection of circulating tumor cells to monitor
the progression of various types of urologic metastatic can-
cers, including prostate cancer, renal cancer, and bladder
cancer [7–9].
These studies mentioned above outline the importance of
understanding the biology of cancer cells that are released
into the circulation and the survival mechanism inherent to
this population of tumor cells. The number of patients with
poor prognosis and clinical outcome from metastatic disease
affirms the importance of understanding the progression of a
tumor cell from the site of origin into the circulatory system.
The ability to detect circulating tumor cells during early-stage
disease may provide potential prognostic value and may aid
in designing more appropriate therapeutic regimens. The
lack of quality detection methods, however, limits the ability
to consistently detect, quantify, and characterize these neo-
plastic cells. Thus, the focus of this review is to outline the
concepts and methods of detection and isolation specifically
in urologic cancers and to discuss the prevailing evidence
regarding the limited techniques employed in studying circu-
lating tumor cells.
Emerging Concepts of Tumor Cell Survival in the Third
Microenvironment and Metastasis
Tumorigenesis and the process of metastasis are comprised
of several intermediate steps [10–14]. The initial phase of
cancer development is organ-confined, localized tumorigen-
esis. Transformation of cells to an oncogenic phenotype
occurs in a defined organ (i.e., prostate, bladder, and so
on) and leads to dysregulated localized cellular proliferation
resulting in tumor development. Multiple factors, both en-
dogenous and exogenous, induce changes in the phenotype
and genotype of oncogenic cells, resulting in aberrant growth
of a subpopulation of tumor cells with increased metastatic
potential. This subpopulation of tumor cells induces angio-
genesis at the site of the primary tumor supplementing the
increasing metabolic needs of the growing tumor mass.
Localized tumor cells secrete factors (e.g., MMP) that
change and breakdown the extracellular matrix (ECM) and
alter homotypic cell-to-cell adherence. Additionally, these
tumor cells become increasingly motile and have enhanced
invasive properties. Subsequently, tumor cells detach from
the primary tumor site and are released into the local
microvascular environment (intravasation).
Currently, it is unclear how circulating tumor cells survive
in this third microenvironment, avoiding innate immune re-
sponse, shear forces, and anchorage independence. Nor-
mally, cells that require anchorage to ECM for survival
Figure 1. Diagrammatic representation of cancer metastasis. Initial localized tumorigenesis (first microenvironment) promotes angiogenesis by the release of a
variety of angiogenic factors (e.g., vascular endothelial growth factor [VEGF], platelet-derived growth factor [PDGF]). Tumor cells secrete proteases matrix
metalloproteinases (MMP) to degrade the extracellular matrices (ECM) and allow the migration of tumor cells into the circulation (third microenvironment). Several
factors are released in response to tumor cell intravasation, including urokinase plasminogen activator (uPA), plasminogen activator inhibitor type-1 (PAI1), and
thrombin, which promote tumor cell survival and metastasis. The aggregation of tumor cells and platelets during transit promotes survival and ultimately
extravasation at the secondary tumor site (second microenvironment). The mechanisms of tumor cell extravasation into the secondary target site of bone are
illustrated in the expanded box. Invading tumor cells have been shown to release factors that stimulate both osteoblastic and osteoclastic activity. OBp, osteoblastic
progenitor cells; OCp, osteoclastic progenitor cells; OB, osteoblast; OC, osteoclast; S, stromal cell; TFAg, Thomas Friedrich antigen; gal 3, galectin 3 receptor;
PTHrp, parathyroid hormone– related protein; SDF, stromal-derived factor.
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undergo spontaneous apoptosis when their adherence to the
ECM is lost. However, tumor cells develop the ability to
survive in an anchorage-independent environment through
acquired phenotypic and genotypic alterations (e.g., expres-
sion of galectin-3 and edg-2) [15]. Several investigators have
demonstrated protection against anoikis—the loss of an-
chorage-dependent cell death—in circulating tumor cells
and have presented this as a possible means for tumor cell
survival. Similarly, heterotypic and homotypic aggregation of
neoplastic cells has been implicated as a possible mecha-
nism for tumor cell survival. Studies have demonstrated that
the ability of tumor cells to adhere in a homotypic fashion
correlates with the metastatic potential and aggressiveness
of a given tumor [16].
There is growing support for the release of tumor cells into
the circulation as an early stage of metastasis that may
precede the clinical identification of the primary tumor, and
a significant correlation between the level of circulating tumor
cells (either by reverse transcription–polymerase chain re-
action [RT-PCR], immunomagnetic separation, or fluores-
cent-activated cell sorting [FACS]) and disease progression
[19] has been demonstrated. Despite the fact that the im-
pact of circulating tumor cells on the metastatic potential,
disease progression, or potential tumor burden of a given
cancer is not clearly understood, the presence of tumor cells
in the peripheral blood and bone marrow is generally accept-
ed and provides the opportunity to study specific tumor cell
populations thought to be responsible for metastasis and
increased tumor burden.
Methods for Detecting Circulating Tumor Cells in
Urologic Cancers
Several methods for detecting circulating cancer cells in
peripheral blood from patients with various urologic cancers
have been developed over the past few decades. These
methods are outline in Table 1 and discussed in greater
detail below.
RT-PCR
Both qualitative and quantitative RT-PCR have been used
as methods to calculate the levels of circulating tumor cells
from whole blood in several types of urologic cancer. RT-
PCR is a highly sensitive amplification method of specific
cDNA sequences based on the design of oligonucleotide
primer probes that recognize the target gene of interest.
Studies have demonstrated the ability of PCR to detect one
circulating tumor cell in 1 to 10 million normal cells using
primer probes to several different target genes [18]. The
advent of PCR technology has provided a specific and
sensitive way to distinguish cells based on differential gene
expression and genetic profiling. The primer probes used to
detect circulating tumor cells from peripheral blood and bone
marrow are designed based on two strategies: 1) amplifica-
tion of tissue-specific markers (i.e., prostate-specific antigen,
or PSA), and 2) general tumor cell characteristics (i.e.,
epithelial cell markers).
The limitations of using PCR to detect circulating tumor
cells include: 1) amplification of nonspecific products, and
2) lack of consistent protocol and primer design between
Table 1. Identification of Circulating Tumor Cells in Peripheral Blood.
Cancer Method of Detection Markers Conclusions Key References
Bladder RT-PCR UPII, CK20 CK19,
EGFR, PSMA
EGFR and UPII expression
may be useful tumor markers
22,29,32,61
IHC CK8, CK18, CK19 CTCs were detected only in patients
with metastatic disease
34
MACS MACS improved sensitivity and
specificity of CTC detection
62,63
FACS E-cadherin, CD103 Flow cytometry allowed isolation of
bladder cancer cells by differential
expression of E- cadherin
64
Prostate RT-PCR PSA, PSMA, PSCA PSA as promising marker for
molecular staging in PCa
49,65
IHC Cytokeratin, PSMA,
DAPI, E-cadherin,
p53, PSA
IHC and in situ hybridization
allow characterization of isolated
cancer cells
66,67
MACS Enrichment of circulating tumor
cells for enhanced genetic analysis
24,68
FACS 5E10, Muc1, CK Flow cytometric isolation is
efficient for CTC detection
17,69
Renal RT-PCR PSMA, MN/CA9 PSMA and MN/CA9 may be
useful as biomarkers for renal cancer
21,39,55
IHC N/A
MACS Increased sensitivity of
detection of cell number and tumor grade
58
FACS N/A
Testicular RT-PCR a-Fetoprotein Inconsistent findings using PCR
to detect circulating tumor cells
in patients with testicular cancer
59,60
IHC N/A
MACS N/A
FACS N/A
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investigators necessary for interlaboratory comparisons
[14,21]. This inherently increases the possibility of non-
specific amplification products due to protocol and primer
design. Nonspecific products include amplification of prod-
ucts from an alternative cell type (e.g., PSA from a non-
prostate cell), detection of pseudogenes due to inadequate
primer design, and detection of products from nonmalig-
nant cells present in the circulation. The lack of adequate
tissue-specific or tumor-specific markers may result in
PCR amplification of false-positives and may be a result
of physical contamination from venipuncture as well as
tumor cell heterogeneity (i.e., epithelial, albumin, and es-
trogen receptors).
The most characterized molecular marker for PCR-based
detection of circulating tumor cells in urologic cancers as well
as other solid tumors is the cytokeratin family. Cytokeratins
are intermediate filament proteins found in epithelial cells
and are commonly used to distinguish epithelial cells from a
heterogenous cell population. However, cytokeratins are
neither specific for tissue type, nor do they distinguish the
origin of the epithelial cells. For example, cytokeratin 20
(CK20) is a cytokeratin originally thought to be specific to
the gastrointestinal epithelium, although its expression has
since been identified in granulocytes, bone marrow, and
whole blood samples from healthy individuals [22,23]. How-
ever, in an alternative experiment, CK20 expression was not
identified in venous peripheral blood isolated from healthy
individuals implicating CK20 as a possible tumor detection
marker [23]. These studies emphasize the conflicting results
obtained from RT-PCR–based detection methods and high-
light the need for standardized laboratory techniques and
preparation protocols to insure proper and consistent inter-
pretation of results. For this reason, gene-specific amplifica-
tion by RT-PCR is now being performed in conjunction with
alternative methods.
Immunohistochemistry
The use of immunohistochemistry for identification and
detection of circulating tumor cells relies on antibody recog-
nition of a specific tissue-type marker or cancer-specific
marker. For example, studies in bladder cancer have used
immunohistochemistry techniques with antibodies for
several of the cytokeratins, CD45 (a tyrosine phosphatase),
carcinoembryonic antigen (CEA), urokinase plasminogen
activator receptor (uPA-R/CD87), and plasminogen acti-
vator inhibitor type-2 (PAI2). Similarly, de la Taille et al.
[23] have used antibodies that recognize PSA and prosta-
tic acid phosphatase (PAP) to detect circulating prostate
cancer cells.
However, opposing data obtained from immunohisto-
chemical techniques have resulted in conflicting opinions
on the reliability and specificity of immunohistochemistry.
The basis for these assays is their ability to recognize cell-
type–specific markers and is dependent on the specificity of
manufactured antibodies and interpretational biases. The
antibodies used for immunohistochemical-based detection
methods must be both specific as well as sensitive to be able
to distinguish between circulating tumor cells and normal
cells. Immunohistochemical analysis of bladder cancer cir-
culating tumor cell tests for molecular markers such as
cytokeratin, nucleic acid staining, CEA, or uPA-R. Although
immunohistochemistry can produce significant results, its
value is contingent on the efficacy of specific antibodies
and discernible expression of proteins. Due to the short-
comings of immunohistochemistry, including sensitivity, re-
producibility, and limited quantitation, it often serves as
merely a confirmatory experiment to alternative assays.
Magnetic Cell Sorting (MACS)
A relatively new technique has been developed using
magnetic nanoparticles coupled to antibodies to specifically
separate circulating tumor cells from whole blood. Immuno-
magnetic cell selection is an attractive method for studying
the biology of circulating tumor cells. This method produces
an enriched sample of circulating epithelial cells that can be
subsequently used for DNA separation, mRNA purification,
cell isolation and detection, development of immunoassays,
capture of biomolecules, and protein purification [21,26].
The process of immunomagnetic cell selection is based
on the recognition of epithelial cell–specific antibodies cou-
pled to magnetic beads. The magnetic beads allow for
isolation and separation of epithelial cells by serial magnetic
incubations. Several companies have designed enrichment
protocols based on immunomagnetic separation (e.g., www.
immunicon.com, www.miltenyibiotec.com, www.stemcell.
com). Briefly, an example of a separation and enrichment
protocol from whole blood is as follows: epithelial cells are
labeled using ferromagnetic nanoparticles coupled to an
epithelial cell adhesion molecule antibody and placed in a
magnetic chamber. Epithelial cell markers are useful in
detecting cancer cells due to the extremely low levels of
circulating epithelial cells in normal individuals. A leukocyte
marker is used to distinguish leukocytes that sometimes
separate with the epithelial cells. Cells are labeled with an
anti–cytokeratin monoclonal antibody (mAb) and placed into
a magnetic field chamber and visualized using a fluorescent
microscope [27]. The cells labeled with the ferromagnetic
nanoparticles are drawn to, and align themselves along,
magnetic lines within the chamber [28]. A microscope scans
the ferromagnetic lines and captures images of the cells
using four different wavelengths, and the images are stored
in a computer. The investigator reviews the cells and counts
the number of cancer cells in the blood sample based on
predefined criteria (Figure 2). To ensure unbiased identifica-
tion of circulating tumor cells, multiple investigators may
review these images.
Once the circulating tumor cells have been isolated from
blood, analysis by flow cytometry using antibodies specific
for subpopulations of cells (i.e., stem cells) or specific cellular
morphologic and functional properties can provide further
understanding of the biology of tumor cells. Similarly, these
same techniques can be employed under sterile conditions,
allowing the purification and enrichment of a tumor cell
population that can be placed as xenografts into immune-
deficient mice, or grown in culture for further molecular and
biologic investigations.
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There are distinct advantages to using the immunomag-
netic cell selection method for enriching circulating tumor cell
populations. One advantage is the visualization and quanti-
fication of circulating tumor cells compared with other meth-
ods including PCR and immunohistochemistry. A second
advantage is that the immunomagnetic selection detects
only intact cells, requiring a nucleus and a stained mem-
brane. PCR detects living cells, dead cells, and free DNA,
resulting in potential false-positives. Similarly, the limitations
of the immunomagnetic enrichment system include cost,
time-consuming process, variability due to nonstandardized
methods and reagents, and inherent circulating tumor cell
variability between patients.
Several studies have started combining the previously
mentioned methods of detection (i.e., RT-PCR, immunohis-
tochemistry, and flow cytometry) in an effort to more effi-
ciently and specifically identify circulating tumor cells. Hu
et al. [29] combined magnetic separation with immunocyto-
chemistry and flow cytometry to enrich and detect circulating
tumor cells from breast cancer patients. They reported an
increased ability to isolate, detect, and identify circulating
tumor cells from whole blood by combining magnetic sepa-
ration and immunocytochemistry. They also reported a sig-
nificant correlation between circulating breast cancer cells
and clinical disease state. Perhaps the best method of
detection employs a combination of enrichment techniques
with specific tissue-type or cell-type marker detection.
Detection of Circulating Tumor Cells in Various Types
of Urologic Cancer
Studieshavereportedattempts to isolate, identify,andclassify
circulating tumor cells from patients diagnosed with various
urologic cancers. The detection method of circulating tumor
cells has mainly been based on gene expression and phe-
notypic characteristics common to neoplastic epithelial cells.
Bladder Cancer
In the United States, approximately 38,000 men and
15,000 women are diagnosed with bladder cancer each year
[30]. Bladder tumors are grouped into several types based on
morphologic criteria and biopsy pathology. The three main
types of cancers that affect the bladder are: urothelial
carcinoma (also known as transitional cell carcinoma, or
TCC), squamous cell carcinoma, and adenocarcinoma.
TCC is responsible for approximately 90% of bladder can-
cers, whereas squamous cell carcinoma and adenocarci-
noma account for the remaining 10%. The cancer origin is
predominantly derived from the lining of the bladder and is
often referred to as a superficial tumor. However, the cancer
may turn invasive and invade the muscle wall, resulting in
the progression of metastatic disease to nearby organs.
A number of investigators have used RT-PCR techniques
to detect and identify micrometastases of bladder cancer
from peripheral blood samples [31–33]. Gazzaniga et al. [34]
reported the use of endothelial growth factor receptor
(EGFR) expression compared with cytokeratin 19 (CK19)
and CK20 by RT-PCR and Southern blot analysis from blood
collected from bladder cancer patients. This study demon-
strated that identification of circulating tumor cells from
peripheral blood by cytokeratin expression is complicated
by false-positives from normal healthy patients. Additionally,
they demonstrated the importance of alternative, supportive
biomarkers if molecular staging were to be pursued as a
prognostic indicator of disease. This group was able to show
no evidence of uroplakin II (UPII) or EGFR in samples from
healthy patients, yet 74% of patients with confirmed meta-
static bladder cancer were positive for EGFR expression
by RT-PCR.
Further studies have used immunohistochemical techni-
ques to detect circulating tumor cells in peripheral blood
from bladder cancer patients [35]. The use of antibodies
directed toward CK8, CK18, and CK19 was aimed to identify
epithelial cells after isolation of mononuclear cells by Ficoll
gradients and fixation. Desgrandchamps et al. [35] were
able to identify epithelial cells in blood samples from 32
patients with TCC of the bladder; however, they could not
distinguish between stage or grade of cancer using immu-
nohistochemistry of circulating epithelial cells. These data
Figure 2. Illustration of cells isolated from peripheral blood by immunomagnetic cell selection and analyzed with a fluorescent microscope. Cells that stain positive
for 4V,6-diamidino-2-phenylindole (DAPI; nuclear stain), positive for CK19 (epithelial cell), and negative for CD45 (lymphocyte) are identified as a circulating tumor
cells. Cells that stain positive for CD45 are identified as lymphocytes.
306 Circulating Tumor Cells in Urologic Cancers Loberg et al.
Neoplasia . Vol. 6, No. 4, 2004
suggest that although the use of molecular targets initially
thought to be specific for circulating tumor cells (i.e., cyto-
keratins) is useful in identifying metastasis, further work is
needed to develop gene expression as a means of progno-
sis and diagnosis in patients.
Prostate Cancer
Prostate carcinoma is the predominant cancer diagnosed
in American men and is the second leading cause of cancer-
related deaths in men. The American Cancer Society esti-
mates that approximately 220,900 men will be diagnosed
with clinically defined prostatic carcinoma and roughly
29,000 men will die from advanced metastatic prostate
cancer in 2003 [30]. Biochemical relapse (a rise in PSA
levels) after definitive treatment occurs in approximately
40% of prostate cancer patients and is indicative of meta-
static disease.
PSA monitoring and radiographic imaging analysis have
been the standards for detecting prostate cancer recurrence
and progression. However, the identification of recurrence at
earlier time points would be extremely advantageous for
immediate therapeutic intervention [36]. Prostate cancer
has been an active area of research for circulating tumor
cells due to several known prostate-specific genes (i.e., PSA
and prostate-specific membrane antigen [PSMA]). There
have been several reports describing methods and strate-
gies used to identify and characterize circulating prostate
cancer cells and to correlate these findings with disease
progression [14,37–39]. Many of these studies have relied
on the sensitivity of PCR-targeted amplification of PSA
and PSMA [40–45].
A variety of studies have reported increased dissemina-
tion and hematogenous spread of prostate cancer cells
following prostatectomy by RT-PCR analysis [46,47]. Simi-
larly, the ability to detect changes in circulating tumor cells
between patients with localized disease and metastatic
disease has been demonstrated, as well as a correlation
between PSA levels and circulating tumor cells [14,48–51].
Gelmini et al. [51] reported the detection of circulating
prostate cells in peripheral blood from patients with meta-
static prostate cancer. This study amplified the PSA gene
using quantitative RT-PCR from blood samples taken from
prostate cancer patients. They reported a reliable detection
of PSA in prostate cancer patients as well as a reduction in
PSA detection after definitive treatment. Additionally, no
detection of PSA was reported in healthy controls.
Alternative methods have been used to detect circulating
prostate cancer cells including flow cytometry, immunohis-
tochemistry, and immunomagnetic separation [52–54]. Flow
cytometry was used to measure circulating PSA-positive
cells obtained from 40 diagnosed, untreated prostate cancer
patients and demonstrated a significant correlation with
metastatic disease [52].
Renal Cancer
The incidence of renal cell carcinoma is estimated to be
31,900 new cases, resulting in approximately 11,900 renal
cancer–related deaths in 2003, placing renal carcinoma in
the top 10 leading cancers [30]. Renal carcinoma typically
has a poor prognosis due to the fact that early detection is
difficult. Currently, there are no specific renal tumor markers
(e.g., PSA for prostate cancer) that are beneficial for diag-
nosis or monitoring. Few studies have focused on detecting
and isolating circulating tumor cells from renal carcinoma
patients [55–58]. Ashida et al. [59] reported the detection of
mutations in the von Hindel-Lindau tumor-suppressor gene
in patients with renal cell carcinoma by nested RT-PCR.
Additionally, the expression of MN/CA9 (a carbonic anhy-
drase isoenzyme) has been the target of RT-PCR amplifica-
tion in peripheral blood samples taken from patients with
renal cell carcinoma [58]. However, although PCR offers a
highly sensitive method to detect genes, the specificity of
the amplified target genes is a limiting factor for its diagnos-
tic or prognostic value. De la Taille et al. [41] described the
use of nested RT-PCR to evaluate PSMA expression in
peripheral blood from renal cancer patients. PSMA has been
thought to be a prostate cell–specific gene and, therefore,
amplification of this gene in blood from renal cancer pa-
tients brings into question the specificity and reliability of this
assay.
Due to the relatively limited number of studies aimed at
detecting and characterizing circulating renal carcinoma
cells from peripheral blood samples, implementing the de-
tection of circulating tumor cells as a prognostic indicator
remains premature. Several techniques and combinations of
techniques are currently being explored. Bilkenroth et al. [60]
have demonstrated an increased sensitivity of renal carcino-
ma detection from peripheral blood by using MACS followed
by immunohistochemical labeling of cytokeratins to identify
tumor cells. The major advantage of this study was the ability
to isolate a highly enriched population of circulating epithelial
(tumor) cells from a small volume of peripheral blood drawn
from patients (i.e., 8 ml of blood). Further studies are
necessary to specifically identify the origin of the circulating
tumor cells and to, perhaps, isolate and identify the circulat-
ing cells necessary for metastasis.
Testicular Cancer
Testicular cancer is one of the leading cancers among
youngmen. The incidence of testicular cancer is estimated to
be 7600 new cases, resulting in approximately 400 renal
cancer–related deaths in 2003 [30]. To date, there has been
limited efforts aimed at detecting and isolating circulating
tumor cells from patients with testicular cancer. The most
recent studies used nested PCR techniques to detect circu-
lating malignant cells from peripheral blood isolated from
patients with germ cell testicular tumors of various stages
and treatment regimens [65,66]. These studies demonstrat-
ed the ability to detect increased levels of a-fetoprotein (AFP)
and b-human chorionic gonadotropin (b-hCG) in peripheral
blood from patients with advanced testicular cancer. Al-
though these studies have demonstrated the ability to detect
the presence of circulating tumor cells in patients with
testicular cancer by PCR, further studies are required to fully
investigate this line of inquiry for possible prognostic value.
Additionally, the alternative methodologies mentioned above
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should be explored and used for detecting and isolating
circulating tumor cells from patients with testicular cancer.
Conclusions
The initial detection methods of circulating tumor cells have
been based on histopathologic techniques and have proven
to be time-consuming and subject to reviewer interpretation.
The development of PCR led to increased sensitivity and
specificity of detection, and removed the subjective influence
inherent in earlier methods of detecting circulating tumor
cells. However, several concerns regarding the specificity of
PCR in detecting circulating tumor cells have been raised
due to the inconsistency of results and amplification of false
products. Recently, a technique has been developed using
magnetic nanoparticles coupled to epithelial cell–specific
antibodies that recognize and isolate circulating tumor
cells from whole blood, allowing for enrichment of tumor
cell sample by a noninvasive clinical procedure. Further
investigation is required to fully develop a series of method-
ologies and protocols aimed at detecting and isolating circu-
lating tumor cells from peripheral blood. The combination of
the methods discussed above may offer an effective, power-
ful means to understanding the mechanism of metastasis
and may lead to new ways of monitoring disease progression
and clinical outcome.
The importance of understanding the mechanisms inher-
ent to circulating metastatic tumor cells that allow the cells to
survive the microenvironment of the circulation is an exciting
area of ongoing research. Identifying these mechanisms is
the next wave of cancer research with great potential for
novel therapeutic targeting of tumor cell survival in the
circulation.
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